文献速递膀胱癌与上尿路尿路上皮癌

根治性膀胱切除术后风险分层与条件复发:迈向适应性随访

Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up.
PubMed 文献 · BJU Int · 2026-03-12

基于16个欧洲中心3196例cT2-T4N0M0膀胱癌根治性膀胱切除患者的回顾性注册数据,采用CART分析建立风险分层模型。高危组(pT3-4或pN+或pT2伴LVI)5年无复发生存率显著低于低危组(37.8% vs 76.2%,P<0.001),HR 4.29(95%CI 3.63-5.00)。条件风险在术后5年后趋于一致(HR 1.37,P=0.3),提示可据此制定风险适应性随访策略。

要点

  • CART模型将患者分为高危(pT3-4/pN+/pT2伴LVI)和低危,5年RFS分别为37.8%和76.2%。
  • 高危组复发风险显著升高(HR 4.29,95%CI 3.63-5.00),且风险持续至术后4年。
  • 无事件患者5年后条件复发风险趋同(HR 1.37,P=0.3),支持风险适应性随访。

核心结论

  • 基于病理的简单模型(pT3-4/pN+/pT2伴LVI)可有效分层根治性膀胱切除术后患者,支持风险适应性随访策略。

研究设计与样本

  • 回顾性分析16个欧洲中心1990-2024年3196例cT2-T4N0M0膀胱癌根治性膀胱切除患者的个体数据注册。
  • 采用CART分析纳入病理T和N分期、淋巴血管侵犯等特征进行风险分层,主要终点为无复发生存。

主要发现

  • 中位随访81.8个月,891例复发。
  • 高危组5年RFS为37.8%,低危组为76.2%(P<0.001)。
  • 风险分层对复发(HR 4.29,95%CI 3.63-5.00)、癌症特异性生存(亚分布HR 5.80)和总生存(HR 3.04)均有显著预后价值(均P<0.001)。
  • 里程碑分析显示高危风险持续至术后4年,无事件患者5年后条件风险趋同(HR 1.37,P=0.3)。

关键数值与推荐

  • 高危组定义为病理T3-T4期、淋巴结阳性或pT2期伴淋巴血管侵犯。
  • 高危组5年RFS 37.8% vs 低危组76.2%(P<0.001),复发HR 4.29(95%CI 3.63-5.00)。
  • 癌症特异性生存亚分布HR 5.80,总生存HR 3.04(均P<0.001)。
  • 5年后无事件患者条件复发HR 1.37(P=0.3)。

临床怎么用

  • 可利用病理特征(pT3-4/pN+/pT2伴LVI)识别高危患者,制定更密集的随访计划。
  • 术后4年内高危患者复发风险持续升高,应加强监测。
  • 5年后无事件患者复发风险趋同,可考虑调整随访强度。

局限性

  • 回顾性研究设计,治疗决策和随访方案由医生酌情决定,存在选择偏倚。
  • 模型需前瞻性评估以确认临床效用、安全性和成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop a data-driven risk-stratification model to identify high-risk patients following radical cystectomy (RC) for bladder cancer and propose a risk-adapted follow-up (FU) schedule. PATIENTS AND METHODS: We performed a retrospective analysis of an individual patient data registry comprising 3196 patients with clinical T stage (cT)2-T4 N0M0 bladder cancer who underwent RC at 16 European centres (1990-2024). All treatment decisions, including the use of neoadjuvant chemotherapy, adjuvant therapy, and the FU schedule, were made at the discretion of the treating physician in accordance with the patient's preference. A Classification and Regression Tree (CART) analysis, incorporating pathological T and N stages, lymphovascular invasion (LVI), and other features, was used to stratify patients into Low-Risk and High-Risk groups for recurrence. The primary endpoint was recurrence-free survival (RFS). We used a landmark analysis to evaluate the conditional risk of recurrence at 1, 2, 3, 4, and 5 years after RC. RESULTS: At a median FU of 81.8 months, 891 patients recurred. CART analysis identified a High-Risk group (pathological T stage [pT]3-pT4, node-positive disease, or pT2 with LVI) with significantly worse 5-year RFS than the Low-Risk group (37.8% vs 76.2%; P < 0.001). This stratification was strongly prognostic for recurrence (hazard ratio [HR] 4.29; 95% confidence interval 3.63-5.00), cancer-specific survival (subdistribution HR 5.80), and overall survival (HR 3.04) (all P < 0.001). Landmark analysis confirmed that the elevated risk persisted up to 4 years; however, the conditional risk for event-free patients converged after 5 years (HR 1.37; P = 0.3). CONCLUSIONS: This study establishes a simple, pathologically derived model (pT3-4/pN+/pT2 + LVI) that effectively stratifies post-RC patients, enabling a risk-adapted FU strategy. Prospective evaluation of this framework is required to confirm its clinical utility, safety, and cost-effectiveness.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Contieri R, Martini A, Furrer M, et al. Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up. BJU Int. 2026. PMID: 41821206. doi:10.1111/bju.70232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。